Low and maternal-specific expression of p57 KIP2 in hydatidiform mole and its clinical implication

Department of Obstetrics and Gynecology, Xiehe Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430022.
Journal of Huazhong University of Science and Technology (Impact Factor: 0.83). 06/2002; 22(2):121-2, 157. DOI: 10.1007/BF02857671
Source: PubMed


In situ hybridization was applied to locate and detect the expression of p57KIP2 in hydatidiform mole (5 cases of partial hydatidiform mole and 18 cases of complete hydatidiform mole) and normal villi (23 cases). The positive signals of p57KIP2 expression were analyzed by HPIAS-1000 Image-Analysis System. p57KIP2 was highly expressed in normal villi but showed distinct low expression in hydatidiform mole (P < 0.01). Furthermore, the locus of low expression of p57KIP2 accorded with the place where lesion of trophoblast occurred. Detection of p57KIP2 made it possible to study the genetics of hydatidiform mole at the transcriptional level. Low expression of p57KIP2 could be a molecular marker in hydatidiform mole and a target for therapy.

4 Reads
  • [Show abstract] [Hide abstract]
    ABSTRACT: Gestational trophoblastic neoplasia refers to the spectrum of conditions characterised by proliferation of conceptus-derived trophoblast, and includes partial and complete hydatidiform mole (HM), invasive mole, choriocarcinoma and placental site trophoblastic tumour and its variants. With changes in the management of early pregnancy complications in recent years, the majority of HMs are now evacuated in the late first trimester, at which time, it is now recognised, their histopathological features, although characteristic, may differ from those traditionally described following second-trimester evacuation. In view of these changes in presentation, updated histopathological criteria are presented and specific additional issues discussed, including recent advances in molecular genetics, ancillary investigations, recurrence risk, development of persistent trophoblastic neoplasia, intraplacental choriocarcinoma and mole with coexisting fetus.
    Current Diagnostic Pathology 06/2007; 13(3):210-221. DOI:10.1016/j.cdip.2007.04.005
  • [Show abstract] [Hide abstract]
    ABSTRACT: Although molar pregnancies are typically defined by morphological, histologic, and genetic criteria, most cases are diagnosed solely on histologic findings. Recently, several studies have demonstrated the usefulness of p57KIP2 immunostaining as an ancillary diagnostic tool for molar pregnancies. The p57KIP2 gene is paternally imprinted and maternally expressed; therefore, the positive staining of its protein indicates the presence of a functional maternal allele. Because complete hydatidiform moles (CHMs) lack a maternal genome, p57KIP2 immunostaining is absent. Previous studies have validated this staining technique by demonstrating differential nuclear expression in CHMs versus non-CHMs; however, these studies have not included cytogenetic analysis. We report on 58 cases of hydropic placentas, correlating cytogenetic and p57KIP2 immunostaining results. In addition, cases with unusual p57KIP2 staining patterns are discussed. Also included are 2 mosaic conceptions (1 diploid/triploid and 1 diploid/tetraploid), 6 chimeric/mosaic conceptions with androgenetic/biparental cell lines, and 2 cases of placental mesenchymal dysplasia.
    Human Pathlogy 02/2008; 39(1):63-72. DOI:10.1016/j.humpath.2007.05.010 · 2.77 Impact Factor
  • [Show abstract] [Hide abstract]
    ABSTRACT: To review the published data on studies examining immunohistochemical markers of hydatidiform moles for determination of diagnosis or prognosis, with regard to whether such investigations can provide clinically relevant information. Search of computerized literature databases to identify studies reporting on immunohistochemical findings in cases of hydatidiform mole followed by summarization and interpretation of the findings. Of 166 studies initially identified, 88 studies were included in the final analysis. Some markers, such as P57(KIP2), show distinct differences in expression between groups and are useful in clinical practice for the diagnosis of complete hydatidiform moles. Some markers appear to be associated with increased risk of progression to requiring chemotherapy, including increased expression of P53, EGFR, HER2, c-erbB-2 and telomerase and reduced expression of nm23. Despite technical issues complicating overall interpretation, such as small sample size and the uncertainty of classification of hydatidiform moles in many studies, convincing data is reported for several markers, which should guide future studies. Insufficient data exists to recommend changes in clinical management based on current evidence.
    The Journal of reproductive medicine 05/2010; 55(5-6):236-46. · 0.70 Impact Factor

Similar Publications